Cho and coworkers show that Ewing's sarcoma cells are highly sensitive to expanded allogeneic natural killer (NK) cells, partially through a NKG2D and DNAM-1 dependent mechanism. Using an orthotopic murine model, they also demonstrate that irradiation significantly enhances the NK cell killing of these tumors.
In this issue of Clinical Cancer Research, Cho et al. demonstrate that immunotherapy using ex vivo expanded natural killer (NK) cells may be an effective treatment for Ewing sarcoma (EWS) (1) . EWS are neural ectodermal tumors with a peak incidence in the second decade of life. While the majority of patients with localized disease can be successfully treated with multimodality therapy (chemotherapy, radiation and surgery), approximately 30% will ultimately relapse. These relapsed patients, as well as those who present with metastatic disease, are unlikely to be cured despite modern therapy, hence, there is a need for new treatments.
Immunological therapies are now being explored for a number of diseases not responsive to standard chemotherapy, including EWS. Allogeneic NK cells are emerging as a promising treatment strategy. In contrast to T cell-and dendritic cell-based therapies, NK cells do not require the identification of tumor antigens, antigen priming or vaccination strategies. Because allogeneic NK cells do not cause graft vs. host disease (GVHD), healthy siblings or parents could be used as donors. Moreover, allogeneic NK cells may be better at killing tumors than autologous NK cells (2) ( below).
NK cytotoxicity is determined by the 'balance' of signaling though numerous activating or inhibitory receptors. In general, the mechanisms that control NK cytotoxicity are skewed to favor inhibition (i.e., tolerance). Inhibitory receptors recognize MHC class I expression and when engaged, cytotoxicity is inhibited. Reductions in MHC class I expression occur during viral infection and malignant transformation, allowing NK cells to recognize "stressed" cells. The two main inhibitory receptors are CD94/NKG2A and killer inhibitory receptors (KIR). The CD94/NKG2A complex recognizes the nonpolymorphic protein, HLA-E, while KIR recognize specific epitopes on HLA-A, -B and -C.
To trigger NK cytotoxicity activating receptors must also be engaged. Over the past 10 years, intensive research has lead to the discovery of NK cell activating receptors. One of the most studied activating receptors is NKG2D, which is expressed on resting NK cells and is up-regulated following activation and cytokine stimulation. This receptor binds to the MHC class I like proteins MICA and MICB, as well as ULBP 1-4. These NKG2D ligands are induced on malignant cells via DNA-damaging signals (irradiation and chemotherapy) (3). Therefore, a main strategy for NK cell based immunotherapy might be to activate NK cells ex vivo (to up-regulate NKG2D), to induce NKG2D ligand expression on tumor tissue in vivo (2) or both.
Other NK activating receptors include 2B4 (recognizing CD48), TRAIL (recognizing DR4/5), several natural cytotoxicity receptors (NCRs: NKp30, NKp44, NKp46, and NKp80) and DNAX accessory molecule-1, (DNAM-1, CD226 Previously, Verhoeven and coworkers demonstrated that EWS cell lines are sensitive to NK cell cytotoxicity (4). They found that NK killing of EWS was mainly mediated through the activating receptors NKG2D and DNAM-1 since antibody blocking significantly attenuated NK cytotoxicity. Moreover, several EWS lines and patient samples were found to express NKG2D and DNAM-1 ligands. Compared to controls, the cytotoxicity of NK cells from EWS patients was decreased, but could be restored following rhIL-15 stimulation in vitro.
In this issue of Clinical Cancer Research, Cho and colleagues use their previously published method to expand NK cells with a K562 feeder cell line that is genetically modified to express membrane-bound IL-15 and 4-1BB ligand (5-6). These cell lines potently activate and expand NK cells over 2-3 weeks in culture. Using these expanded NK cells, Cho tested the cytotoxicity against EWS, rhabdomyosarcoma, neuroblastoma, and osteosarcoma (1) . Among these, a number of EWS lines were extremely sensitive to allogeneic NK cells from healthy donors (median cytotoxicity is 87.2% at 1:1 E:T). Similar to Verhoeven (4), Cho presents some data supporting the involvement of NKG2D and DNAM-1 in tumor recognition since blocking these receptors attenuated killing (1). However, there was a poor correlation between NKG2D and DNAM-1 ligand expression and cytotoxicity; perhaps suggesting that other activating receptors may also be operational in EWS killing, but the differences in the results between the two laboratories may also reflect varying techniques of NK cell activation and expansion.
One of the major clinical goals in the upcoming years will be to determine how to integrate immunotherapy into current treatment regimens. As described above, NK cells recognize stressed or abnormal cells. One form of cell stress is chemotherapy and irradiation induced tissue injury which, on malignant tissue, may increase the expression of NK activating ligands. Thus, research has started to focus on whether tumors can be "sensitized" to NK killing. Unfortunately, Cho demonstrates that EWS lines treated with relevant chemotherapy agents (doxorubicin or vincristine) did not induce expression of the ligands for NKG2D and DNAM-1 (1). In contrast, this approach was successful in multiple myeloma and increased the susceptibility to NK mediated attack (7) . Therefore, elucidation of other chemotherapeutic agents that might sensitize EWS cells to NK killing may be useful for combination chemo-immunotherapy.
